Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston
LUND, Sweden ― Immunovia today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized. This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilitating commercialization, covering marketing, sales and customer support.
A highly skilled team with a proven track record of successfully establishing and scaling up CLIA accredited reference laboratories based on ground breaking new technologies have been recruited to carry out the US market first introduction, in the second half of 2018.
Mats Grahn, CEO Immunovia, comments: “The market introduction of IMMrayTMPanCan –d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia. We have therefore chosen to establish our USA operations headquarters in Boston, which is the major biotech hub in the world. A very experienced laboratory team will be moving into Immunovia´s own reference laboratory that will cover Eastern USA, adding to our commercial group that will also be located at the Boston facilities. This East coast laboratory complements the existing collaboration we have with Knight Diagnostic Laboratories in Portland, serving Western USA. I consider this an important stepping stone in our US commercialization strategy.”
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
The Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and require clinical laboratories to be certificated by their state as well as the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct.